Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
- 1 October 2005
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 59, S387-S392
- https://doi.org/10.1016/s0753-3322(05)80085-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinomaBreast Cancer, 2005
- Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast CancerClinical Cancer Research, 2004
- Significance of histopatholoaical evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response(pCR) as endpointBreast Cancer, 2004
- Present role and future perspectives of the evaluation of the effect of primary chemotherapy by breast imagingBreast Cancer, 2004
- Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.Annals of Surgical Oncology, 2004
- International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and RecommendationsJournal of Clinical Oncology, 2003
- Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapyBreast Cancer, 2002
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancerThe American Journal of Surgery, 1998
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998